Introduction
Understanding the cell of origin of tumors is important not only for elucidating detailed mechanisms of tumorigenesis but also for characterizing the context in which tumor cells develop, both of which provide useful information that can inform preventive therapy and therapeutic strategies in the clinical setting (Visvader, 2011) . Stem cells and multi-potent progenitor cells are believed to be prone to tumors because their cellular characteristics are similar to tumor cells. We recently demonstrated that well-differentiated osteosarcomas arise from immature bone marrow (BM) stromal cells, including mesenchymal stem cells, as the cell of origin, in a mouse model (Shimizu et al., 2010) . However, it remains unresolved whether the cell of origin of hematopoietic malignancies, such as B-cell lymphoid tumors composed of differentiated tumor cells, is derived from stem cells, progenitor cells or committed (differentiated) cells (Cobaleda and Sanchez-Garcia, 2009 ). Furthermore, to date, only a few studies have compared the characteristics of tumor cells derived from distinct cells of origin.
Deregulated expression of Myc oncogenes (c-Myc, N-Myc and L-Myc) is frequently found in solid tumors as well as in hematopoietic tumors, and is often associated with a poor prognosis (Meyer and Penn, 2008) . Myc is a potent oncogene that can directly induce hematopoietic tumors such as Burkitt's lymphoma, acute myeloid leukemia and acute lymphoid leukemia (ALL) in mouse models (Adams et al., 1985; Luo et al., 2005; Kawagoe et al., 2007) . In Em-Myc transgenic mice, animals develop lymphoid tumors that are likely derived from committed B cells, since Myc expression in this model is controlled by the immunogloblin enhancer promoter (Adams et al., 1985) . On the other hand, enhanced expression of c-Myc in fetal liver cells, including mainly hematopoietic stem and progenitor cells, induces committed B-cell lymphoma (Hemann et al., 2005) . Thus, stem cells, progenitor cells and differentiated cells could be the cell of origin for lymphoid tumors induced by Myc.
To clarify the cell of origin of hematopoietic tumors, we introduced the Myc oncogene into various fractions of mouse BM mononuclear cells (BM-MNCs). Both hematopoietic stem cells (HSCs) and committed progenitor B cells were able to serve as the cell of origin for precursor B acute lymphoblastic leukemia/lymphoma (pre-B ALL/ LBL) induced by Myc, but the development of pre-B ALL/LBL directly from progenitor B cells was subject to certain molecular limitations. Furthermore, the therapeutic outcomes were different depending on the cell of origin, even though the tumor cells were similar in terms of immunophenotype and histopathology. Our findings implicate a novel therapeutic concept for the treatment of pre-B ALL/LBL derived from distinct cells of origin.
Results

Myc rapidly induces pre-B ALL/LBL in immature BM-MNCs
We attempted to establish the mouse hematopoietic tumor model using BM-MNCs from the adult mouse. We used a conventional method based on the BM transplantation assay because it is easier to establish tumors with short-term latency and to distinguish cell sub-populations by differentiation markers. Given that N-Myc recently has been reported to have more tumorigenic activity than c-Myc in hematopoietic tumor (Kawagoe et al., 2007) , we first used N-Myc for tumor induction. Retroviral vectors for N-Myc and N-Myc lacking the Myc Box II (DMBII) domain, an important region for transactivation, were constructed (Supplementary Figure 1a ). BM-MNCs were isolated from mice after 5-FU treatment, which enriches immature cells, and then infected with retroviral vectors. Infected cells were injected intravenously into lethally irradiated mice (Supplementary Figure 1b) . Six weeks after transplantation, GFP-positive cells and the number of peripheral blood mononuclear cells in mice transplanted with NMyc-transduced BM-MNCs were significantly higher than mice transplanted with control-or DMBII-transduced cells (Figures 1a and d) . All mice transplanted with N-Myc-transduced BM-MNCs died after B2 months (Figure 1b) . On the other hand, mice transplanted with control-or DMBII-transduced cells showed no signs of tumor growth over a period of 300 days. Tumor-bearing mice had enlarged lymph nodes and thymus and exhibited splenomegaly ( Figure 1c) . As seen by H&E staining, tissue destruction was readily apparent in BM, lymph nodes and liver that had been invaded and were occupied by tumor cells (Figure 1d ). Flow cytometry analysis showed that almost all tumor cells were negative for the myeloid markers Mac1 and Gr1, positive for the B-cell markers B220 and CD19, and positive-to-negative for the precursor B-cell marker CD43 (CD43 þ , pro-B; CD43 À , pre-B), and tumor cells were also negative for the mature B-cell marker IgM (Figure 1e ). Based on histopathology and immunophenotype, the tumors were classified as pre-B ALL/LBL (Morse et al., 2002) . We further found that transplantation HSCs exhibit the highest susceptibility to Myc-induced pre-B ALL/LBL, and B220 þ tumor cells can serve as the tumor-initiating cells for secondary tumors HSCs give rise to common lymphoid progenitors (CLPs) and myeloid progenitors (MPs). CLPs are differentiated to committed progenitor B cells that ultimately become mature B cells (Supplementary Figure 2a) . To identify the cell of origin of Myc-induced pre-B ALL/LBL, we separated three main populations, HSCs, MPs and CLPs in N-Myc-transduced BM (GFP þ ) cells (Figure 2a ). MPs (61.9%) constituted the greatest sub-population in NMyc-transduced BM cells. Sorted cells were transplanted into lethally irradiated mice with supportive BM-MNCs. Based on limiting dilution analysis, as few as 100 HSCs were sufficient to induce pre-B ALL/LBL, whereas 41000 CLPs and 10 000 MPs were necessary to induce tumors, and these had longer latencies than HSCsderived tumors (Table 1) . Tumor cells and tissues from mice transplanted with HSCs had a similar immunophe-
) and similar histopathology to those derived from N-Myc-transduced bulk BM-MNCs (Figures 2b and c) . All mice that were injected with CLPs and two of the mice transplanted with MPs developed pre-B ALL/LBL (Supplementary Figures  2b and c) . The tumor cells of one mouse transplanted with MPs were positive for Gr-1 and slightly positive for CD3 and B220. Although the difference of the frequency in numbers of tumor-initiating cells between HSCs and MPs was statistically significant (Po0.01), the difference of the frequency in those cells between HSCs and CLPs was not (P ¼ 0.261). However, the frequency of tumorinitiating cells was threefold higher in HSCs (1:184) than in CLPs (1:558) . N-Myc did not simply enrich HSCs after retroviral transduction because the populations of N-Myc-transduced HSCs, CLPs and MPs were similar to control cells infected with empty vector (Supplementary Figure 2d) . Collectively, these results suggest that HSCs are the most likely candidate for the cell of origin of Mycinduced pre-B ALL/LBL in immature BM-MNCs.
We next performed secondary transplantation of pre-B ALL/LBL tumor cells. Interestingly, none of the tumor cells derived from N-Myc-transduced HSCs expressed both the HSC markers c-kit and sca-1 (Figure 2d ). Therefore, GFP þ B220 þ BM-MNCs from tumor-bearing mice were sorted and transplanted into sublethally irradiated mice (Figure 2e ). Mice that received a secondary transplant of GFP þ B220 þ cells developed pre-B ALL/LBL with shorter latency than the primary tumor ( Table 2 ). The frequency of tumor-initiating cells was 1:216 based on limiting dilution analysis. These results suggest that there are tumor-initiating cells capable of developing secondary tumors within the B220 þ cell population in the mouse pre-B ALL/LBL model. (Figures 3a and b, left) . Transplanted N-Myctransduced progenitor B cells failed to induce tumors, even when 50 000 cells were injected (Table 3 ). These data suggest that more highly differentiated cells in the hematopoietic lineage are less susceptible to N-Mycinduced tumorigenesis.
Recent reports have suggested a close correlation between the self-renewing activity of normal tissue stem cells and inactivation of Ink4a and Arf. We recently showed that loss of Ink4a and Arf is required for the development of c-Myc-induced osteosarcoma-initiating cells from BM stromal cells (Shimizu et al., 2010) . Here, we isolated progenitor B cells derived from Ink4a/Arfdeficient mice (Figure 3b , right) and used them for retroviral transduction and transplantation. Mice that received N-Myc-transduced Ink4a/Arf À/À progenitor B cells developed pre-B ALL/LBL with a shorter latency than mice transplanted with N-Myc-transduced wild-type (WT) HSCs ( 
) and histopathology to those that originated from WT HSCs (Figures 3c and d) . In addition, we found that c-Myc also induced pre-B ALL/LBL from Ink4a/Arf À/À progenitor B cells (Supplementary Figure 3a) . These results suggest that Myc can directly transform committed progenitor B cells in the absence of Ink4a and Arf, and that Ink4a and Arf are critical determining factors of the cell of origin. 
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Tumor cells derived from Ink4a/Arf À/À progenitor B cells are more resistant to Ara-C treatment and grew faster than tumor cells derived from WT HSCs To characterize potential differences in drug sensitivity between pre-B ALL/LBL tumors derived from N-Myctransduced WT HSCs and Ink4a/Arf À/À progenitor B cells, tumor-bearing mice were administered four doses of daily intraperitoneal Ara-C (Cano et al., 2008) , which is a standard chemotherapeutic agent for the treatment of hematopoietic tumors. Four days after the first injection of Ara-C, the number of tumor cells in peripheral blood was decreased in both types of pre-B ALL/LBL mice ( Figure 4a ). However, tumor cells derived from Ink4a/Arf À/À progenitor B cells had a significantly greater surviving population and exhibited regrowth at a much faster rate than those from WT HSCs (Figure 4a ). To confirm this sensitivity to Ara-C in vitro, tumor cells were harvested from BM and then Cell of origin in Myc-induced lymphoid tumor E Sugihara et al cultured for several days before being treated with Ara-C for 48 h. The results of Annexin V staining showed that tumor cells from Ink4a/Arf À/À progenitor B cells had a significantly greater population of surviving cells (Annexin V-negative cells) after Ara-C treatment than those from WT HSCs at several different concentrations of Ara-C (Figure 4b ). Moreover, tumor cells from Ink4a/Arf À/À progenitor B cells exhibited a faster growth rate than those from WT HSCs in vitro (Figure 4c ). These results suggest that tumor cells that lack Ink4a and Arf are more refractory to Ara-C treatment and show faster growth.
Arf is a key factor in determining the cell of origin of pre-B ALL/LBL The expression of Ink4a and Arf is normally maintained at a low level to endow HSCs with self-renewing capacity. The polycomb protein Bmi1 suppresses the expression of both genes through promoter methylation of the CDKN2A locus in HSCs (Park et al., 2003; Iwama et al., 2004) . To analyze how these genes were regulated in committed progenitor B cells, N-Myc-transduced HSCs and progenitor B cells from WT mice were fractionated, and the expression of Ink4a, Arf and Bmi1 was measured by quantitative real-time RT-PCR. Ink4a expression in N-Myc-transduced progenitor B cells was similar to that in HSCs, whereas Arf expression was significantly higher (4200 fold; Figure 5a ). On the other hand, Bmi1 expression in progenitor B cells was significantly lower than in HSCs. The levels of transduced N-Myc expression were similar in both HSCs and progenitor B cells. Moreover, Arf expression in progenitor B cells transduced with the control vector was also significantly higher than that in control HSCs (Figure 5b 
-derived tumor cells (Figure 5d ). Thus, these findings suggest that Arf has a predominant role in determining the cell of origin of pre-B ALL/LBL.
The Mdm2 inhibitor Nutlin-3 restores p53 and thereby effectively induces apoptosis in tumor cells derived from Ink4a/Arf À/À progenitor B cells Mdm2, a negative regulator of the tumor suppressor protein p53, functions as an E3 ubiquitin ligase to ubiquitinate p53, which leads to p53 degradation (Wade et al., 2010) . Nutlin-3 is a small molecule inhibitor that prevents Mdm2 binding to p53 (Vassilev et al., 2004) and has recently been evaluated as a novel, targeted agent in leukemia therapy (Kojima et al., 2005; Gu et al., 2008) . Since Arf inhibits Mdm2 binding to p53, we hypothesized that Nutlin-3 might substitute for Arf and reactivate p53 in tumor cells derived from Ink4a/Arf À/À progenitor B cells. Nutlin-3 treatment induced extensive apoptosis in cultured Ink4a/Arf À/À progenitor B cell-derived tumor cells (Figure 6a, left) . In fact, all three tumor cell clones were effectively killed by Nutlin-3 treatment in a concentration-dependent manner (Figure 6a, right) . The sequence of the p53 gene was confirmed as WT in all three clones. In contrast, Nutlin-3 was relatively ineffective against tumor cells derived from WT HSCs and WT bulk BM cells, which contained mutations in the p53 in the DNA-binding region ( Supplementary Figures 4a and b) . Following Nutlin-3 treatment, p53 and the apoptosis indicator cleaved caspase-3 were increased in tumor cells derived from Ink4a/Arf À/À cells (Figure 6b ). The p53 targets p21 and Mdm2 were also increased by Nutlin-3 treatment. Furthermore, Ink4a/Arf À/À -derived tumor cells expressing p53 shRNA showed significant reduction of Nutlin-3-induced apoptosis compared with those cells expressing control luciferase shRNA, confirming that the Nulin-3-induced apoptosis is p53 dependent (Figure 6c ).
We next investigated the effect of co-treatment with Ara-C and Nutlin-3 on tumor cells from Ink4a/Arf À/À progenitor B cells. For this analysis, we examined tumor cells of clone 1, as they were less sensitive to 2.5 mM Nutlin-3 compared with the other clones (Figure 6a , right). Although treatment with Ara-C (0.25 mg/ml) or Nutlin-3 (2.5 mM) alone did not efficiently induce apoptosis (24.7 and 39.5%, respectively), combination treatment with Ara-C and Nutlin-3 had a synergistic effect on enhancing apoptosis (75.5%) in tumor cells from Ink4a/Arf À/À progenitor B cells (Figure 6d , left). Nutlin-3 effectively killed tumor cells when combined with different concentrations of Ara-C (Figure 6d, right) . Cell of origin in Myc-induced lymphoid tumor E Sugihara et al
Collectively, these data suggest that Nutlin-3 may be effective in eradicating tumor cells lacking Ink4a and Arf.
Nutlin-3 effectively induces apoptosis in human B-ALL cell lines lacking expression of Ink4a and Arf We attempted to apply our finding that lack of Ink4 and Arf expressions and p53 status can affect chemotherapeutic efficacy to human B-ALL cells. Six human B-ALL cell lines including PALL-2, NAGL-1, NALM-6, HAL-01 (these four lines have WT p53), BALL-1 and Tanoue (both two lines have mutated p53: D281G and M246T, respectively) were treated with Nutlin-3 or Ara-C for 48 h. Nutlin-3 treatment significantly induced apoptosis in cell lines with WT p53 but not in cell lines with mutated p53 (Figure 7a ). Furthermore, real-time Cell of origin in Myc-induced lymphoid tumor E Sugihara et al quantitative RT-PCR showed that the cell lines with WT p53 did not express Ink4a and Arf genes whereas the cell lines with mutated p53 express Ink4a and/or Arf (Figure 7b ). In terms of Ara-C sensitivity, p53 status was not a critical determination factor. Because, although BALL-1 cells having mutated p53 were more sensitive to Ara-C treatment than cell lines with WT p53, Tanoue cells having mutated p53 were even less sensitive to Ara-C (Supplementary Figure 4c) . Collectively, these results suggest that Nutlin-3 effectively induces apoptosis in human B-ALL cell lines with WT p53 and lacking expression of Ink4a and Arf, which is a similar result to mouse pre-B ALL/LBL cells.
Discussion
In this study, we demonstrated that N-Myc rapidly induced pre-B ALL/LBL originated from HSCs, whereas it could not induce any tumor directly from committed progenitor B cells due to limiting factors Ink4a and Arf. Furthermore, tumor cells derived from distinct cells of origin showed different drug sensitivities to Ara-C and Nutlin-3, which provide a novel insight into preventive therapy and different therapeutic approaches depending on genetic background of tumor cells (Figure 7c ). In our mouse model, there is no significant difference between two types of Myc oncogenes, N-Myc and c-Myc, in respect to tumorigenic activities and chemotherapeutic sensitivities of the induced tumors (Figures 4b and 6a ; Supplementary  Figures 3b and c) . Overexpression of these Myc genes has been reported in a number of B-ALL patients, suggesting a pathophysiological relevance between Myc and human B-ALL (Cardone et al., 2005) . Tumor-initiating cells in human B-ALL that have the potential to self-renew and generate secondary tumors reportedly express normal HSC markers, that is, CD34 þ , CD38 À and/or B-cell markers, that is, CD10 þ and CD19 þ (Cobaleda et al., 2000; Cox et al., 2004; Castor et al., 2005; Hotfilder et al., 2005; Hong et al., 2008; le Viseur et al., 2008) . In the current syngenic mouse model, tumor-initiating cells capable of generating secondary tumors were identified in the B-cell marker-positive cell population, not the HSC markerpositive cell population, which corroborates the fact that there are tumor-initiating cells that are positive for B cell markers in human B-ALL. Interestingly, the tumorinitiating cells that develop primary tumors were part of the HSC marker-positive cell population. This difference in the tumor-initiating cells between primary and secondary tumors indicates that HSCs that express Myc can essentially disappear, developing into committed progenitor B cells during transformation. Previous reports have suggested that the enhanced expression of Myc results in the migration of HSCs from the BM niche, thereby promoting the commitment to progenitor cells (Wilson et al., 2004) . The expansion and transformation of Myc-transduced cells are believed to occur at the stage of progenitor B cell. Recently, it was reported that c-Myc is involved in the regulation of pro-B expansion as a downstream effector in the MAPK signaling pathway (Yasuda et al., 2008) , which suggests that progenitor B cells are the most suitable candidate for Myc-induced expansion. Our findings raise the possibility that Myc-transduced HSCs initially give rise to multi-hematopoietic lineages, and then progenitor B cells gain an Myc-induced proliferative advantage and become dominant. Ultimately, these expanding progenitor B cells acquire additional mutations, for example, p53 mutations, and become fully transformed.
The cell of origin of B-ALL has long been debated and is assumed to be stem cell or immature progenitor cell (Cobaleda and Sanchez-Garcia, 2009 ). We demonstrated that HSCs from the BM of adult mice are the primary origin/target in pre-B ALL/LBL. HSCs express functional Bmi1, which suppresses the expression of Ink4a and Arf and enables the cells to maintain their self-renewing capacity. Bmi1 has been reported to suppress Arf-dependent apoptosis induced by Myc to enhance lymphomagenesis (Jacobs et al., 1999) . It is possible that HSCs are more potent to receive N-Myc overexpression without inducing apoptosis. On the other hand, no tumors were induced directly from WT committed progenitor B cells. Given that Arf is expressed in progenitor B cells much higher than Ink4a, and that N-Myc was able to induce tumor derived from Arf À/À progenitor B cells, Arf represents a predominant factor in the determination of the cell of origin of Mycinduced pre-B ALL/LBL, similar to its role in the mouse model of BCR-ABL-induced B-ALL (Wang et al., 2008) . It should be noted that tumor cells derived from WT cells carried mutations in p53, indicating that inactivation of the Arf-p53 pathway is critical for B lymphoid tumorigenesis, consistent with previous results (Eischen et al., 1999) . Abbreviation: WT, wild type.
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Following Ara-C treatment in vitro and in vivo, tumor cells derived from Ink4a/Arf À/À progenitor B cells were more refractory to apoptosis and showed faster regrowth compared with those derived from WT HSCs. Previous reports suggest that Ink4a/Arf À/À lymphoma cells display reduced p53 activity and thereby escape Cell of origin in Myc-induced lymphoid tumor E Sugihara et al from apoptosis and/or senescence programs induced by p53 and Ink4a (Schmitt et al., 1999 (Schmitt et al., , 2002 . Fast growth of Ink4a/Arf À/À tumor cells may arise from a fact that Arf-null pre-B cells show canceling Arf-p53 checkpoint, and thus promote Myc-induced proliferation (Eischen et al., 1999) . Although tumors that originated from WT HSCs carried mutated p53, these cells expressed high levels of Ink4a and Arf (Supplementary Figure 4d) . Ink4a and Arf have crucial roles in the induction of apoptosis and Arf can also induce apoptosis independently of p53 (Ausserlechner et al., 2001; Tsuji et al., 2002) . The heightened sensitivity of tumor cells from WT HSCs to Ara-C treatment compared with those from Ink4a/Arf À/À progenitor B cells may reflect a p53-independent mechanism of apoptosis by Ink4a and Arf.
The CDKN2A locus is deleted or inactivated in nearly half of all cases of B-ALL, especially Ph þ B-ALL and recurrent types of B-ALL (Mullighan et al., 2008a, b) . To date, there has not been a good mouse model for understanding and developing treatments for these types of malignant ALL. The mouse model of pre-B ALL/ LBL derived from Ink4a/Arf À/À progenitor B cells developed in the current study could be such a suitable model. In testing novel therapeutic approaches with this model, we used Nutlin-3 to inhibit p53-Mdm2 binding because all of the tumor clones derived from Ink4a/Arf À/À progenitor B cells had WT p53, and p53 gene mutations are relatively infrequent in cases of chronic myelogenous leukemia (CML) lymphoid blast crisis, in which Arf loss predominates (Calabretta and Perrotti, 2004) . We demonstrated that Nutlin-3 treatment reactivated p53 and drastically induced apoptosis in tumor cells derived from Ink4a/Arf À/À progenitor B cells. Recently, it was reported that Nutlin-3 is effective against human B-ALL cells with WT p53 (Gu et al., 2008) . We found that Nutlin-3 treatment effectively induced apoptosis in human B-ALL cell lines with WT p53 and lacking Ink4a and Arf expression, and thereby the concept we obtained from our established pre-B ALL/LBL mouse model can be applied to human B-ALL. We further tested combination treatment with Ara-C and Nutlin-3 in consideration of the clinical setting (Kojima et al., 2006) . In this case, relatively low dose of Nutlin-3 acted synergistically to enhance Cell of origin in Myc-induced lymphoid tumor E Sugihara et al apoptosis induced by Ara-C in tumor cells derived from Ink4a/Arf À/À progenitor B cells. These results suggest that the upregulation of p53 by Nutlin-3 enhances Ara-C-induced apoptosis. If a tumor is classified as pre-B-ALL according to histopathology and immunophenotype, additional analysis to determine genetic background, such as p53 mutation or Ink4a/Arf inactivation, could inform the most appropriate therapeutic strategy for an individual patient.
Materials and methods
Mice WT C57BL/6 mice (6-8-week-old) were purchased from Charles River Japan Inc. (Atsugi, Japan). Ink4a/Arf À/À mice (B6.129-Cdkn2a tm1Rdp ) were obtained from Mouse Models of Human Cancers Consortium (NCI-Frederick). Arf À/À mice were described previously (Kamijo et al., 1997) and kindly provided by CJ Sherr (St Jude Children's Hospital). Animals were cared for in accordance with the guidelines of the Keio University School of Medicine.
Human cell lines
Two human B-ALL cell lines PALL-2 and NAGL-1 were obtained from Health Science Research Resources Bank (HSRRB) (Osaka, Japan). The other human B-ALL cell lines NALM-6, HAL-01, BALL-1 and Tanoue were obtained from RIKEN Cell Bank (Tsukuba, Japan). NAGL-1 was maintained in IMDM (Invitrogen, San Diego, CA, USA) supplemented with 20% FCS and the other cell lines were maintained in RPMI (Sigma, St Louis, MO, USA) supplemented with 10% FCS at 37 1C in 5% CO 2 and 100% humidity.
Retroviral vectors, transduction and BM transplant assay
Mouse N-Myc and DMBII cDNAs were cloned into the retroviral vector pMXs-IG. Mouse Bmi1 cDNA was cloned into pMXs-IRES-DsRed. The empty vector was used as a control. The pMX-based vectors were transfected into Plat-E packaging cells (Morita et al., 2000) using Fugene HD (Roche, Mannheim, Germany) and then the cells were allowed to incubate overnight at 37 1C in 5% CO 2 . The medium was replaced 24 h after transfection. Viral supernatants were filtered using a 0.45-mm cellulose acetate filter (Iwaki, Tokyo, Japan) after 48 h of incubation. Procedures of retroviral infection and BM transplant assay are described in Supplementary Methods.
Flow cytometry BM-MNCs from tumor-bearing mice were stained with allophycocyanin-conjugated anti-B220, phycoerythrin-conjugated CD43, CD19 (all from Biolegend, San Diego, CA, USA) and IgM antibodies (eBioscience, San Diego, CA, USA). Samples were analyzed using a FACSCalibur system (BD Biosciences, San Diego, CA, USA). Cell sorting is described in Supplementary Methods.
Ara-C and Nutlin-3 treatment
Tumor-bearing mice were treated intraperitoneally with 100 mg/kg of cytosine arabinoside (Ara-C, Sigma) for 4 consecutive days. Peripheral blood was lysed with red blood cell lysis buffer and then counted. For the apoptosis assay, cells were incubated in the presence or absence of Ara-C and/ or Nutlin-3 (Kojima et al., 2005) for 48 h. Assays for detection of apoptosis and BrdU incorporation are described in Supplementary Methods.
Immunoblot analysis
Cells were lysed and denatured as previously described (Sugihara et al., 2006) . Samples were separated by SDS-PAGE and then proteins were transferred onto a PDVF membrane (GE Healthcare, Piscataway, NJ, USA). Membranes were incubated for 1 h at room temperature in blocking buffer consisting of 5% non-fat dry milk in phosphatebuffered saline with 0.05% Tween-20, followed by an appropriate dilution of anti-p53 (FL-393), anti-Mdm2 (SMP14), anti-p21 (C-19) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-cleaved caspase-3 (Cell Signaling Technology, Danvers, MA, USA) or anti-a-tubulin (Sigma) primary antibody overnight at 4 1C. Membranes were incubated with horseradish peroxidase-conjugated secondary antibody (GE Healthcare) for 45 min at room temperature. Peroxidase activity was detected by Western lightning chemiluminescence reagents (Perkin-Elmer, Boston, MA, USA).
Statistical analysis
Differences between two groups were compared using the two-tailed unpaired Student's t-test. P-values in frequency of tumor-initiating cells based on limiting dilution analysis were calculated with extreme limiting dilution analysis (ELDA) (Hu and Smyth, 2009 ). Po0.05 was considered statistically significant.
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